Drug Profile
Getagozumab - Gmax Biopharm
Alternative Names: GMA-301; GMA-301A; GMA-301BLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Gmax Biopharm
- Class Antihypertensives; Monoclonal antibodies
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pulmonary arterial hypertension
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension(In volunteers) in Australia (IV, Injection)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension(In adolescents, In children, In infants) in China (IV, Injection)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Pulmonary-arterial-hypertension in China (IV, Injection)